Rocket Pharmaceuticals (RCKT) Enterprise Value (2016 - 2025)
Rocket Pharmaceuticals (RCKT) has disclosed Enterprise Value for 10 consecutive years, with -$300.3 million as the latest value for Q4 2025.
- Quarterly Enterprise Value rose 19.35% to -$300.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$300.3 million through Dec 2025, up 19.35% year-over-year, with the annual reading at -$300.3 million for FY2025, 19.35% up from the prior year.
- Enterprise Value hit -$300.3 million in Q4 2025 for Rocket Pharmaceuticals, down from -$222.8 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$222.8 million in Q3 2025 to a low of -$648.7 million in Q3 2023.
- Historically, Enterprise Value has averaged -$389.6 million across 5 years, with a median of -$351.5 million in 2022.
- Biggest five-year swings in Enterprise Value: tumbled 111.63% in 2023 and later soared 63.67% in 2024.
- Year by year, Enterprise Value stood at -$388.7 million in 2021, then increased by 8.32% to -$356.4 million in 2022, then decreased by 4.71% to -$373.2 million in 2023, then grew by 0.22% to -$372.3 million in 2024, then rose by 19.35% to -$300.3 million in 2025.
- Business Quant data shows Enterprise Value for RCKT at -$300.3 million in Q4 2025, -$222.8 million in Q3 2025, and -$271.5 million in Q2 2025.